Rocbrutinib plus R-CHOP yielded a 100% ORR and an 86.7% CR rate in 15 patients with untreated non-GCB DLBCL, warranting randomized evaluation.
Rutika Mehta, MD, MPH, shares her framework for growth factor support, global dose reductions, and dropping agents during FLOT therapy. In an interview with CancerNetwork®, Rutika Mehta, MD, MPH, ...
Preoperative botensilimab plus balstilimab produced a pathologic major response in 36% of patients with pMMR and 100% of those with dMMR resectable colon cancer. Short-course neoadjuvant botensilimab ...
Grade 3/4 neurotoxicity in patients prompted a partial clinical hold on the PALISADES-1 and PALISADES-2 trials of KITE-753 in large B-cell lymphoma. Preoperative botensilimab plus balstilimab produced ...
Mark Burkard, MD, PhD, discussed genomic gaps, extreme survivors of metastatic breast cancer, and how minimal residual ...
Rutika Mehta, MD, MPH, discusses perioperative durvalumab plus FLOT and first-line options for patients with low or negative ...
Sunnie Kim, MD, discusses postoperative management for patients without a pathologic response after neoadjuvant durvalumab ...
In a prospective cohort, a 3-gene blood model predicted 1-year castration resistance with an AUC of 0.89 in metastatic ...
Rutika Mehta, MD, MPH, explains how she sequences MSI, HER2, claudin 18.2, and PD-L1 testing when tissue is limited in gastroesophageal cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results